The mission of the Bioinformatics Core (BIC) is to provide bioinformatics support for diverse approaches to cancer research in the COHCCC. The BIC collaborates with COHCCC governance committees to promulgate standards, optimize systems and minimize redundancy through continued integration of data, databases, applications and processes for enabling cost effective, collaborative, translational research. Since the last competitive renewal, the BIC has been working with experts in the field to establish a scalable high performance cyber-infrastructure equipped with close to 500 TB tiered storage repository with high bandwidth network connection, integrated cloud computing with internal TBs shared memory servers with more than 4000 hyper-threaded CPU and GPGPU processors, and external cloud computing to maximize both our infrastructure investment and provide infrastructure-on-demand. In addition, the BIC provides integrated laboratory information management systems (LIMS), which harbor research information portals shared among multiple core facilities (e.g., Functional Genomics and Genomic Sequencing, Drug Discovery and Structural Biology, Analytical Cytometry, Small Animal Imaging, and the developing Proteomics and Translational Research cores). The BIC also provides researchers with high-throughput biological data analysis, including integration with high-quality publicly available multi-disease, multi-cohort gene expression datasets. With highly-trained staff working in multidisciplinary teams, the BIC facilitates experimental design, QC/QA, data analysis, integration, annotation, dissemination, visualization and training for researchers. A new subscription-based chargeback policy was implemented in 2009 to offer tiered services to COHCCC members to be included in their grant proposals for adequate chargeback. The usage has nearly doubled from 45 subscribers in 2008 to 78 in 2010, and chargeback revenue has tripled from $46,487 in 2008 to $141,078 in 2010. Between 2007 and 2011, the BIC was used by a total of 88 principal investigators, 67 of whom are COHCCC members, and BIC staff collectively co-authored 52 peer-reviewed publications. The BIC's ongoing goal is to foster comprehensive bioinformatics support for researchers to enable collaborations among, basic, translational, clinical and population sciences researchers.

Public Health Relevance

The overall goal of the Bioinformatics Core facility is to provide COHCCC investigators with high-throughput biological data analysis tools, data management and cyber-infrastructure, and training to foster collaborations and develop modern computational techniques. This goal enables the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-30
Application #
8450536
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2017-11-30
Budget Start
2013-04-25
Budget End
2013-11-30
Support Year
30
Fiscal Year
2013
Total Cost
$188,453
Indirect Cost
$76,279
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications